- What the Market Looks Like?
- What are Key Trends in the Market?
A lack of awareness and access to digital therapeutics programs in developing countries, patient data privacy concerns, unstable payment models, and resistance from traditional healthcare providers are challenging the growth of this market to a certain extent.
What the Market Looks Like?
According to the new market research report by MarketsandMarkets, the global digital therapeutics market is projected to reach USD 6.9 billion by 2025 from USD 2.1 billion in 2020, at a CAGR of 26.7% during the forecast period (2020–2025). North America accounted for the largest share of the digital therapeutics market in 2019.
The growth of the digital therapeutics market is primarily driven by factors such as government initiatives for preventive healthcare, technological advancements in mobile healthcare, a significant increase in venture capital investments, and the benefits of digital therapeutics, such as the ability to induce behavioral change (an important challenge in healthcare), user-friendliness, patient convenience, and improved drug compliance.
What are Key Trends in the Market?
The growth of the Digital Therapeutic (DTx) Market is primarily influenced by the following factors:
- Increasing incidence of preventable chronic diseases
- Rising focus on preventive healthcare
- Need to control healthcare costs
- Significant increase in venture capital investments
Based on the type of buyer, the B2C sales channel market is further segmented into patients and caregivers. The caregivers segment is expected to dominate the market and register the highest CAGR during the forecast period. The high growth of this segment is attributed to company initiatives for the development of products specifically for caregivers and the fact that digital therapeutics help caregivers in better managing their patients.
Read more about DTx Market @ Sample Request - Digital Therapeutics Market | Growing at a CAGR of 26.7% | MarketsandMarkets
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.